Serum EDN as a novel biomarker for severe eosinophilic adult asthma
Main Article Content
Keywords
severe asthma, type 2 inflamation, eosinophil-derived neurotoxin
Abstract
Background: Eosinophilic inflammation is a major pathophysiological mechanism in severe asthma (SA). However, a reliable serum biomarker reflecting this type of inflammation has not yet been identified. Therefore, in this study, we aimed to investigate whether serum levels of eosinophil-derived neurotoxin (EDN) could serve as a biomarker for predicting the diagnosis of SA in adult patients with asthma.
Methods: A total of 89 patients, including 52 with SA and 37 with nonsevere asthma (NSA), were included in the study, all having PBEC ≥ 150 cells/µL. The relationships between serum EDN and serum eosinophilic cationic protein (ECP) levels with peripheral blood eosinophil count (PBEC), as well as with clinical and demographic parameters, were assessed. In addition, the clinical validity of serum EDN and PBEC levels in predicting the SA phenotype was evaluated.
Results: A correlation analysis among PBEC, serum EDN, and serum ECP levels revealed statistically significant positive correlations: between PBEC and serum ECP (p<0.001), PBEC and serum EDN (p<0.001), and serum ECP and serum EDN (p=0.002). Serum EDN and PBEC levels were significantly higher in the SA group compared to the NSA group (225.40 [0.001–588.76] vs. 380.05 [0.001–1920.45], p<0.001; 290 [160–820] vs. 335 [170–2070], p=0.003, respectively). Regarding spirometric parameters, FEV1 (mL and %), FVC (mL and %), and FEF25–75 (mL and %) values were significantly lower in the SA group compared to the NSA group. In the receiver operating characteristic (ROC) curve analysis evaluating the predictive value of serum EDN levels for identifying the SA phenotype, a sensitivity of 69% was observed. In univariate analysis, both serum EDN and PBEC levels were significantly associated with SA. However, multivariate analysis demonstrated that only serum EDN levels remained a statistically significant independent predictor of the SA phenotype.
Conclusions: Serum EDN emerged as an independent predictor of the SA phenotype and demonstrated superior diagnostic performance compared with conventional eosinophilic markers. These findings highlight its potential as a promising biomarker for identifying SA and reflecting underlying type 2 airway inflammation.
References
2. Mortimer K, Lesosky M, García-Marcos L, Innes Asher M, Pearce N, Ellwood E et al. The burden of asthma, hay fever and eczema in adults in 17 countries: GAN phase I study. Eur. Respir. J. 2022;60:2102865. https://doi. org/10.1183/13993003.02865-2021
3. Asher MI, Rutter CE, Bissell K, Chiang CY, El Sony A, Ellwood E et al. Worldwide trends in the burden of asthma symptoms in school-aged children: global asthma network phase I cross-sectional study. Lancet. 2021;398:1569–1580. https:// doi.org/10.1016/S0140-6736(21)01450-1
4. Konig IR, Fuchs O, Hansen G, von Mutius E, Kopp MV. What is precision medicine? Eur. Respir. J. 2017;50:1700391. https:// doi.org/10.1183/13993003.00391-2017
5. Busse WW, Rosenwasser LJ. Mechanisms of asthma. J. Allergy Clin. Immunol. 2003; 111:S799–S804. https://doi.org/10.1067/mai.2003.158
6. Kim CK, Callaway Z, Pawankar R. Eosinophil granule proteins as a biomarker in managing asthma and allergies. Asia Pac. Allergy. 2023 Jun;13(2):66–71. https://doi.org/10.5415/ apallergy.0000000000000104
7. Saitoh O, Kojima K, Sugi K, Matsuse R, Uchida K, Tabata K, et al. Fecal eosinophil granule-derived proteins reflect disease activity in inflammatory bowel disease. Am. J. Gastroenterol. 1999;94:3513–3520. https://doi. org/10.1111/j.1572-0241.1999.01640.x
8. Rutten B, Young S, Rhedin M, Olsson M, Kurian N, Syed F, et al. Eosinophil- derived neurotoxin: a biologically and analytically attractive asthma biomarker. PLoS One. 2021;16:e0246627. https://doi.org/10.1371/journal.pone.0246627
9. Lee Y, Lee JH, Yang EM, Kwon EM, Jung CG, Kim SC, et al. Serum levels of eosinophil-derived neurotoxin: a biomarker for asthma severity in adult asthma. Allergy Asthma Immunol. Res. 2019;11:394–405. https://doi.org/10.4168/aair.2019.11.3.394
10. Agache I, Strasser DS, Klenk A. Agache C, Farine H, Ciobanu C et al. Serum IL-5 and IL-13 consistently serve as the best predictors for the blood eosinophilia phenotype in adult asth-matics. Allergy. 2016;71:1192–1202. https://doi.org/10.1111/ all.12906
11. Kim CK. Eosinophil-derived neurotoxin: a novel biomarker for diagnosis and monitoring of asthma. Korean J. Pediatr. 2013;56(1):8–12. https://doi.org/10.3345/kjp.2013.56.1.8
12. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur. Respir. J. 2014;43:343–73. https://doi.org/10.1183/09031936.00202013
13. Malinovschi A, Rydell N, Fujisawa T, Borres MP, Kim CK. Clinical potential of eosinophil-derived neurotoxin in asthma management. J. Allergy. Clin. Immunol. Pract. 2023 Mar;11(3):750–761. https://doi.org/10.1016/j.jaip.2022.11.046
14. Färdig M, Lie A, Borres MP, Ekenkrantz T, Granum B, Haugen G, et al. Eosinophil-derived neurotoxin levels in early childhood and association with preschool asthma—a prospective observational study. Clin. Exp. Allergy. 2023 Nov;53(11):1198–1211. https://doi.org/10.1111/cea.14409
15. Kim CK, Callaway Z, Fletcher R, Koh YY. Eosinophil-derived neurotoxin in childhood asthma: correlation with disease severity. J. Asthma. 2010;47:568–73. https://doi. org/10.3109/02770901003792833
16. Hussain M, Liu G. Eosinophilic asthma: pathophysiology and therapeutic horizons. Cells. 2024 Feb 23;13(5):384. https:// doi.org/10.3390/cells13050384
17. An J, Lee JH, Sim JH, Song WJ, Kwon HS, Cho YS, et al. Serum eosinophil-derived neurotoxin better reflect asthma control status than blood eosinophil counts. J. Allergy Clin. Immunol. Pract. 2020 Sep;8(8):2681–2688.e1. https://doi. org/10.1016/j.jaip.2020.03.035
18. Jang JH, Woo SD, Lee Y, Kim CK, Shin YS, Ye YM, et al. Changes in type 2 biomarkers after anti-IL5 treatment in patients with severe eosinophilic asthma. Allergy Asthma Immunol. Res. 2021 Mar;13(2):330–338. https://doi. org/10.4168/aair.2021.13.2.330